Prosecution Insights
Last updated: April 18, 2026
Application No. 18/115,303

TWO-PHOTON FLUORESCENT PROBES FOR SIMULTANEOUSLY DETECTING CALCIUM IONS IN ORGANELLES AND LYSOSOMAL PROTONS

Non-Final OA §103
Filed
Feb 28, 2023
Examiner
VU, JAKE MINH
Art Unit
1618
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Daejin University Center For Educational Industrial Cooperation
OA Round
1 (Non-Final)
40%
Grant Probability
Moderate
1-2
OA Rounds
4y 1m
To Grant
68%
With Interview

Examiner Intelligence

Grants 40% of resolved cases
40%
Career Allow Rate
318 granted / 787 resolved
-19.6% vs TC avg
Strong +28% interview lift
Without
With
+27.5%
Interview Lift
resolved cases with interview
Typical timeline
4y 1m
Avg Prosecution
40 currently pending
Career history
827
Total Applications
across all art units

Statute-Specific Performance

§101
0.4%
-39.6% vs TC avg
§103
39.9%
-0.1% vs TC avg
§102
22.6%
-17.4% vs TC avg
§112
21.6%
-18.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 787 resolved cases

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Receipt is acknowledged of Applicant’s Restriction Requirement Response filed on 01/20/2026; and IDS filed on 02/28/2023. Claims 1-18 are pending in the instant application. Claims 4-18 are withdrawn from further consideration. Election/Restrictions Applicant’s election without traverse of Group I claims 1-3) in the reply filed on 01/20/2026 is acknowledged. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-3 is/are rejected under 35 U.S.C. 103 as being unpatentable over KIM (US 2012/0035360). KIM teaches two-photon fluorescent probes (see title), such as the compound (I) (see [0011]; and is provided below), wherein X is O (see [0012]): PNG media_image1.png 183 266 media_image1.png Greyscale KIM’s nitrogen has a methyl group, while Applicant’s nitrogen has a hydrogen. However, there is case law that holds that compounds that differ in only having H vs Me is not deemed a patentable advance absent evidence of superior and unexpected results. Note In re Wood 199 USPQ 137; In re Lohr 137 USPQ 548; In re Fauque 121 USPQ 425. Thus, it would have been obvious to one skilled in the art at the time the invention was made to modify the closest (i.e. anticipated) compound pointed out above by modifying the nitrogen with hydrogen in place of the methyl. Note, the prior art’s compound would be capable of the intended use as recited by Applicant, unless proven otherwise. Telephonic Inquiries Any inquiry concerning this communication or earlier communications from the examiner should be directed to JAKE MINH VU whose telephone number is (571)272-8148. The examiner can normally be reached Mon-Fri 9:00am-5:30pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Hartley can be reached at (571) 272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JAKE M VU/Primary Examiner, Art Unit 1618
Read full office action

Prosecution Timeline

Feb 28, 2023
Application Filed
Apr 02, 2026
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594245
Dry Powder Formulations for Messenger RNA
2y 5m to grant Granted Apr 07, 2026
Patent 12584173
METHODS FOR DISEASE TREATMENT AND DRUG DISCOVERY
2y 5m to grant Granted Mar 24, 2026
Patent 12582615
TOPICAL ANALGESIC GEL COMPOSITIONS
2y 5m to grant Granted Mar 24, 2026
Patent 12582676
Hydrogel Particle Encapsulated Viable Cells for In Vivo Regenerative Treatment
2y 5m to grant Granted Mar 24, 2026
Patent 12576169
SILICON-FLUORIDE ACCEPTOR SUBSTITUTED RADIOPHARMACEUTICALS AND PRECURSORS THEREOF
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
40%
Grant Probability
68%
With Interview (+27.5%)
4y 1m
Median Time to Grant
Low
PTA Risk
Based on 787 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month